drugset / Trial / NCT05886205
Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy
Phase 0
Unknown
34 enrolled
Peking Union Medical College Hospital
Guidon Pharmaceutics Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the safety, tolerability, and preliminary efficacy of GD-iEXo-002 nasal drops in the treatment of focal refractory epilepsy
Timeline
- Start
- 2023-06-05
- Primary completion
- 2025-06-13
- Completion
- 2025-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iPSC-Exos | Unknown | 2 ug | Intranasal |
| Subject | iPSC-Exos | Unknown | 6 ug | Intranasal |
| Subject | iPSC-Exos | Unknown | 18 ug | Intranasal |